PMC:7148425 / 7060-8565 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"87","span":{"begin":442,"end":445},"obj":"Gene"},{"id":"88","span":{"begin":124,"end":132},"obj":"Species"},{"id":"89","span":{"begin":300,"end":306},"obj":"Species"},{"id":"90","span":{"begin":769,"end":773},"obj":"Species"},{"id":"91","span":{"begin":961,"end":971},"obj":"Species"},{"id":"92","span":{"begin":1171,"end":1181},"obj":"Species"},{"id":"93","span":{"begin":157,"end":166},"obj":"Disease"},{"id":"94","span":{"begin":326,"end":331},"obj":"Disease"},{"id":"95","span":{"begin":1032,"end":1052},"obj":"Disease"}],"attributes":[{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Gene:920"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Tax:694009"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Tax:9606"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"Tax:119216"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"Tax:2697049"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D007239"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"MESH:D005334"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

2_test

{"project":"2_test","denotations":[{"id":"32300370-26459351-46535325","span":{"begin":525,"end":526},"obj":"26459351"},{"id":"32300370-24642138-46535326","span":{"begin":1078,"end":1079},"obj":"24642138"},{"id":"T83295","span":{"begin":525,"end":526},"obj":"26459351"},{"id":"T89624","span":{"begin":1078,"end":1079},"obj":"24642138"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-PMC-OGER-BB

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T39","span":{"begin":384,"end":408},"obj":"Body_part"},{"id":"T40","span":{"begin":403,"end":408},"obj":"Body_part"},{"id":"T41","span":{"begin":457,"end":462},"obj":"Body_part"},{"id":"T42","span":{"begin":486,"end":494},"obj":"Body_part"},{"id":"T43","span":{"begin":1191,"end":1199},"obj":"Body_part"},{"id":"T44","span":{"begin":1202,"end":1206},"obj":"Body_part"},{"id":"T45","span":{"begin":1223,"end":1227},"obj":"Body_part"},{"id":"T46","span":{"begin":1420,"end":1424},"obj":"Body_part"}],"attributes":[{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma273565"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A46","pred":"fma_id","subj":"T46","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T24","span":{"begin":124,"end":132},"obj":"Disease"},{"id":"T25","span":{"begin":157,"end":166},"obj":"Disease"},{"id":"T26","span":{"begin":319,"end":331},"obj":"Disease"},{"id":"T27","span":{"begin":599,"end":608},"obj":"Disease"},{"id":"T28","span":{"begin":709,"end":718},"obj":"Disease"},{"id":"T29","span":{"begin":961,"end":969},"obj":"Disease"},{"id":"T30","span":{"begin":1032,"end":1040},"obj":"Disease"},{"id":"T31","span":{"begin":1043,"end":1052},"obj":"Disease"},{"id":"T32","span":{"begin":1171,"end":1179},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0020502"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T57","span":{"begin":98,"end":99},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T58","span":{"begin":300,"end":306},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T59","span":{"begin":308,"end":309},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T60","span":{"begin":403,"end":408},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T61","span":{"begin":413,"end":414},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T62","span":{"begin":442,"end":445},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T63","span":{"begin":457,"end":462},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T64","span":{"begin":665,"end":668},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T65","span":{"begin":884,"end":889},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T66","span":{"begin":973,"end":980},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9443"},{"id":"T67","span":{"begin":1021,"end":1028},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9479"},{"id":"T68","span":{"begin":1082,"end":1083},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T69","span":{"begin":1200,"end":1206},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T70","span":{"begin":1221,"end":1227},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T71","span":{"begin":1387,"end":1390},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T72","span":{"begin":1404,"end":1405},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T73","span":{"begin":1418,"end":1424},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":288,"end":296},"obj":"Chemical"},{"id":"T8","span":{"begin":384,"end":391},"obj":"Chemical"},{"id":"T9","span":{"begin":425,"end":432},"obj":"Chemical"},{"id":"T10","span":{"begin":447,"end":449},"obj":"Chemical"},{"id":"T11","span":{"begin":1151,"end":1158},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_33385"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T40","span":{"begin":0,"end":34},"obj":"Sentence"},{"id":"T41","span":{"begin":35,"end":78},"obj":"Sentence"},{"id":"T42","span":{"begin":79,"end":183},"obj":"Sentence"},{"id":"T43","span":{"begin":184,"end":307},"obj":"Sentence"},{"id":"T44","span":{"begin":308,"end":528},"obj":"Sentence"},{"id":"T45","span":{"begin":529,"end":621},"obj":"Sentence"},{"id":"T46","span":{"begin":622,"end":797},"obj":"Sentence"},{"id":"T47","span":{"begin":798,"end":972},"obj":"Sentence"},{"id":"T48","span":{"begin":973,"end":1081},"obj":"Sentence"},{"id":"T49","span":{"begin":1082,"end":1331},"obj":"Sentence"},{"id":"T50","span":{"begin":1332,"end":1505},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":326,"end":331},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Biomarkers and vaccine requirement\nThere are few precedents to assist us here. Efforts to develop a prophylactic vaccine or SARS-CoV-1 were shelved when the infection faded by itself. There are surprisingly few data available concerning the status of immune responsiveness to truly novel antigens in humans. A study on Yellow Fever vaccination of the elderly pointed to dysfunctional antigen-presenting cells and a dearth of antigen-specific CD4+ Th helper cells as culprits in the low antibody responses of older vaccinees [7]. Otherwise, we have to rely mostly on the large literature on seasonal influenza vaccination. However, the problem here is that everyone has already been exposed to some strains of influenza and even newly-emerging strains such as the avian H7N1 are not entirely novel. Nonetheless, knowledge garnered on immunity and responses to vaccination against this virus may tell us something about the capacity of older adults to respond to SARS-CoV-2. Primate models featuring the responses of older monkeys to SARS-CoV-1 infection may also be informative [8]. A systems biology approach will be needed to identify the protective antigen/epitopes of SARS-CoV-2 for both antibody/B cell responses and T cell responses and to classify them as protective or non-protective responses to serve as useful biomarkers. Importantly, vaccine design for the older adult should aim to stimulate a broad T and B cell response potentially overcoming reduced immune function in the older population."}

PMC:7148425 / 7060-8565 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7148425 / 7060-8565 JSON TXT